Regorafenib
- Generic Name
- Regorafenib
- Brand Names
- Stivarga
- Drug Type
- Small Molecule
- Chemical Formula
- C21H15ClF4N4O3
- CAS Number
- 755037-03-7
- Unique Ingredient Identifier
- 24T2A1DOYB
- Background
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
- Indication
Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumour (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. Regorafenib is also indicated for the treatment of patients with hepatocellular carcinoma (HCC) previously treated with sorafenib.
- Associated Conditions
- Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Gastrointestinal Stromal Tumor (GIST), Locally advanced Gastrointestinal stromal tumor, Unresectable Gastrointestinal stromal tumor
- Associated Therapies
- -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
- Conditions
- Interventions
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 219
- Registration Number
- NCT03994601
- Locations
- ๐บ๐ธ
Local Institution - 0075, Costa Mesa, California, United States
๐บ๐ธLocal Institution - 0050, Orange, California, United States
๐ช๐ธLocal Institution - 0024, Majadahonda, Spain
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
- Conditions
- Metastatic Colorectal CarcinomaStage III Rectal Cancer AJCC v8Stage IIIB Colon Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIB Rectal Cancer AJCC v8Stage IIIC Colon Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IVA Colon Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage IV Rectal Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 12
- Registration Number
- NCT03992456
- Locations
- ๐บ๐ธ
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธAllegheny General Hospital, Pittsburgh, Pennsylvania, United States
๐บ๐ธMassachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Global Coalition for Adaptive Research
- Target Recruit Count
- 1030
- Registration Number
- NCT03970447
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธUniversity of California, San Diego, La Jolla, California, United States
๐บ๐ธCedars Sinai - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
- Conditions
- Interventions
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Humanity & Health Medical Group Limited
- Target Recruit Count
- 30
- Registration Number
- NCT03899428
- Locations
- ๐ญ๐ฐ
Humanity & Health Research Centre, Hong Kong, Hong Kong SAR, Hong Kong
Zinc Supplement in Regorafenib Treated mCRC Patient
- Conditions
- Interventions
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 65
- Registration Number
- NCT03898102
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2019-03-21
- Target Recruit Count
- 153
- Registration Number
- NCT03880877
- Locations
- ๐จ๐ณ
Chung-Ho Memorial Hospital, Kaohsiung Medical University:, Kaohsiung, Taiwan
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAnatomic Stage IV Breast Cancer AJCC v8AnemiaAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin LymphomaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveCastration-Resistant Prostate Carcinoma
- Interventions
- Drug: AbemaciclibDrug: AbirateroneDrug: AfatinibBiological: BevacizumabDrug: BicalutamideProcedure: Biospecimen CollectionDrug: BortezomibDrug: CabazitaxelDrug: CabozantinibDrug: CapecitabineDrug: CarboplatinDrug: CelecoxibDrug: CobimetinibDrug: CopanlisibDrug: DabrafenibDrug: DacomitinibDrug: DarolutamideDrug: DasatinibDrug: DoxorubicinBiological: DurvalumabDrug: EnasidenibDrug: EntrectinibDrug: EnzalutamideDrug: ErlotinibDrug: EverolimusDrug: FluorouracilDrug: IdelalisibDrug: ImatinibBiological: IpilimumabDrug: LenvatinibDrug: LeucovorinDrug: LorlatinibDrug: LosartanDrug: Nab-paclitaxelDrug: NeratinibBiological: NivolumabDrug: OlaparibDrug: OxaliplatinDrug: PalbociclibDrug: PanobinostatBiological: PembrolizumabBiological: PertuzumabDrug: PonatinibOther: Quality-of-Life AssessmentDrug: RegorafenibDrug: RuxolitinibDrug: SirolimusDrug: SorafenibDrug: SunitinibDrug: TrametinibBiological: Trastuzumab EmtansineDrug: TretinoinDrug: VemurafenibDrug: VenetoclaxDrug: VismodegibDrug: Vorinostat
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03878524
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
- Conditions
- Refractory Colorectal CarcinomaStage IIIC Colorectal Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT03844620
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) Patients
- Conditions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 716
- Registration Number
- NCT03829852
- Locations
- ๐จ๐ณ
Taipei Veterans General Hospital, Taipei, Taiwan
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2023-09-28
- Target Recruit Count
- 78
- Registration Number
- NCT03829462
- Locations
- ๐ซ๐ท
Centre Antoine Lacassagne, Nice, Alpes-Maritimes, France
๐ซ๐ทCentre Franรงois Baclesse, Caen, Basse-Normandie, France
๐ซ๐ทHรดpital Pontchaillou, Rennes, Ile Et Vilaine, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.